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Abstract
More than 100 countries around the world currently require or permit
International Financial Reporting Standards (IFRS) reporting in 2009. When U.S.
companies convert from U.S.Generally Accepted Accounting Principles (U.S. GAAP)
to IFRS, they are faced with great challenges as well as opportunities to make choices
on financial reporting policies. A survey of leading European pharmaceutical
companies that used U.S. GAAP prior to the IFRS adoption was conducted to
evaluate their first-time adoption of IFRS practices. The survey results are structured
into three aspects and discussed in this thesis. First, IFRS 1 optional exemptions at
transition date. Second, key accounting differences from IFRS to U.S. GAAP
reconciliation, and the third, choices of alternative accounting methods allowed by
IFRS. U.S. pharmaceutical companies can learn from these results to choose IFRS 1
optional exemptions to their best interest, to prepare reconciliation between U.S.
GAAP and IFRS and to make accounting choices under IFRS for their first time
adoption of IFRS. These results not only provide benchmark information, but also
provide U.S. companies a cost-effective pathway in making their reporting choices in
the near future when U.S. companies convert from U.S. GAAP to IFRS.

Introduction
For the past several years, there has been strong momentum building toward using
a set of high quality global accounting standards that could be applied by companies
and understood by investors around the world. Currently, more than 100 countries
around the world have adopted International Financial Reporting Standards (IFRS)
reporting (Tsakumis, Campbell, & Doupnik, 2009). Approximately 85 of those
countries require IFRS reporting for all domestic and listed companies, including
Germany, France, Italy, and England. More and more global players will sooner or
later convert to IFRS, including Japan and Canada (Mirza, Orrell & Holt, 2008). The
IFRS conversion is more than just a technical accounting practice. It could have a
significant impact on accounting policies, internal controls, financial reporting and
disclosure and related parties (Thomas, 2003).
United States Securities and Exchange Commission (SEC) has made
groundbreaking movement regarding IFRS. It made an announcement on November
15, 2007 to allow foreign private issuers to enter the US capital market using IFRS
financial statements. This was considered a historical move. For the existing foreign
registrants, they do not need to provide a reconciliation to be based on U.S. Generally
Accepted Accounting Principles (U.S. GAAP) if accepted international accounting
standard such as IFRS is used (SEC. 2007). The SEC released a long-awaited road
map indicating the course of action for U.S. public companies converting to IFRS.
The SEC proposed Roadmap is set forth as such: proposed voluntary application of
IFRS will be permitted for some U.S. registrants at fiscal years ending after December
15, 2009. During 2011, the SEC will reconvene to decide whether a mandatory
conversion date should be set. Proposed roadmap requires all U.S. public companies
to report financial statements using IFRS in 2014 (SEC, 2008). Considering this
financial crisis now, the SEC acknowledges that the pace for roadmap is slowing
down (Forgeas, 2009). However, “SEC chief accountant James Kroeker said the
roadmap would be an important priority this fall”, and we can expect to hear more
about IFRS from Commission (AICPA, 2009).

Many publicly traded European Union (EU) companies used U.S. GAAP to
prepare their consolidated financial statements for various strategic reasons prior to
the IFRS mandate . Majority of European pharmaceutical companies such as
AstraZeneca,

Glaxosmithkline,

Merck,

Novarits,

Novo

Nordisks,

Roche,

Sanofi-Aventis and Schering have already adopted IFRS since 2005 or even earlier
(Ernst &Young, 2006). When U.S. companies convert from U.S. GAAP to IFRS, they
will be faced with great challenges as well as chances in making choices on financial
reporting policies. U.S. pharmaceutical companies can benefit from these European
companies by learning how they applied the guidance provided in IFRS 1 and
selected new IFRS accounting policies as they begin to prepare for their first IFRS
financial statements. By using IFRS, companies can reduce reporting costs, have
greater access to world capital markets, and increase their ability to move accounting
personnel around countries (AICPA, 2009). However, the disadvantage of converting
to IFRS faced by all U.S. companies is the conversion cost. In November 2008, SEC
provided an estimate of $32 million for the conversion cost for companies that would
qualify for the early transition in 2009 (Forgeas, 2009). The pharmaceutical industry,
compared to other industries, faces many challenges in converting to IFRS and needs
more attention because its uniqueness in each of the following areas: revenue
recognition, development costs, and intangible assets (Ernst & Young, 2006).
This study surveys the transition reporting practices and accounting choices
adopted by eight leading European Union pharmaceutical companies, which are
cross-listed in the U.S. and have successfully switched to IFRS from U.S. GAAP.
Their experience with conversion to IFRS from U.S. GAAP is valuable for U.S.
issuers because they are equivalent to U.S. issuers to the extent that they had used U.S.
GAAP for their consolidated financial statements until 2007. The research tools
include SEC EDGAR Company Search, Business Database: Financial Markets and
Services and Net Advantage.
The survey results of these pharmaceutical companies are structured into three
sections:
(1) IFRS 1 optional exemptions

(2) Key differences between IFRS and U.S. GAAP reconciliation
(3) Choices of alternative accounting methods allowed by IFRS.
(4) Important accounting policies
In addition to the four sections above, this thesis also includes a discussion of
determinants of accounting choices and an appendix.
Table 1 is a list of surveyed pharmaceutical companies which adopted IFRS in
preparing their annual report and had used U.S. GAAP before converting to IFRS.
These companies can thus provide direct comparison between IFRS and U.S. GAAP.
［Insert Table 1 here］
］

1. IFRS 1 Optional Exemptions
The International Accounting Standards Board (IASB) published IFRS 1,
First-time Adoption of International Financial Reporting Standards. IFRS 1
established the transition requirements for the first-time adopter to prepare the
financial statements under IFRS. It requires a first-time adopter to apply IFRS at the
reporting date retrospectively. Thus, these companies are presented as if they had
always used IFRS for financial reporting. IFRS 1 contains mandatory exemptions to
retrospective application in certain areas. IFRS 1 also provides optional exemptions to
the general restatement in certain areas in which retrospective application is difficult
or costs would exceed the benefits to the users of financial statements, areas such as
business combination and cumulative translation difference. The purpose of these
optional exemptions is to ease the burden of first-time adoption of IFRS (Deloitte,
2004). Table 2 below summarizes optional exemptions provided by IFRS 1.
［Insert Table 2 here］
］

Summary of Elected Optional Exemptions
Consistent with Hwang and Lin (2009), I focus on the four most commonly used
optional exemptions, which are presented in Table 3. In the following discussion, I
first list the rule of exemption option provided under IFRS 1 in applying a particular
standard (The option II refers to the full retrospective restatement of an IFRS
standard). I then report survey results and relevant excerpts as to how companies
apply an exemption so US companies can learn to prepare such discussions.
GPC Biotech converted to IFRS from U.S. GAAP in the year of 2005 but did not
provide IFRS financial statements until 2007, in which it did not provide first time
adoption practices. Thus it is excluded from the discussion of optional exemptions but
kept for other parts of this thesis. Table 3 below summarizes the most commonly used
optional exemptions by the seven pharmaceutical companies.
［Insert Table 3 here］
］

1.1 Item 1: IFRS 3R Business combinations
For transactions qualifying as business combinations under IFRS 3, an entity can
choose to:
I. Not restate business combinations before the date of transition, (i.e. full
exemption applied)
II. Restate all business combinations before the date of transition, (i.e.,
retrospective application)
III. Restate all business combinations starting from a date it select prior to the date
of transition. (i.e., partial exemption applied)
In all cases, the entity must apply IAS 36 impairment guidance to any remaining
goodwill in the opening IFRS balance sheet, after reclassifying, as appropriate,
previous GAAP intangibles to goodwill.
Survey Results for Item 1
Elan, Shire, MediGene, World of Medicine and Schwarz applied option I by not
restating business combinations before the date of transition. Evotec and Sygnis did
not take and discuss this option in their annual reports. In conclusion, Five out of
seven pharmaceutical companies applied option I by not restating business
combinations before the date of transition. This approach must have saved these
companies money and effort. Basically, it can be concluded that it is in the company’s
best interest not to restate any business combination that occurred before the transition
date.
Excerpts from option I adopters:
Elan–from 2005 Annual Report page156
“Business combinations undertaken prior to the transition date of 1 January 2004
have not been subject to restatement and accordingly, goodwill at the transition date
is carried forward at its net book value and is subject to annual impairment testing in
accordance with IAS 36, ‘‘Impairment of Assets.””
Shire–from 2005 Annual Report page102

“The Group has applied the business combination exemption in IFRS 1. It has not
restated business combinations that took place prior to the January 1, 2004 transition
date in accordance with IFRS 3, “Business Combinations””.
MediGene–from 2005 Annual Report page55
The previous accounting principles for corporate mergers carried out before the
transition date (January 1, 2004) would not be adapted to the new principles.
World of Medicine–from 2005 Annual Report page37
“Business combinations accounted for prior to the period of transition to IFRS, prior
to January 1, 2004, were not retroactively adjusted to IFRS 3”.
Schwarz–from 2005 Annual Report page39
The following exemptions from retrospective adjustment were elected pursuant to
IFRS 1:
“Business combinations (IFRS 1.15): Goodwill from historic acquisitions of
companies measured and carried forward under US GAAP is carried forward in the
opening balance sheet. The balance sheet values as per 1 January 2004 were tested
for impairment pursuant to IAS 36”.

1.2 Item 3: IAS 19 Employee benefits on actuarial gains and losses
An entity may elect to:
I. Recognize all cumulative actuarial gains and losses for all defined benefit plans as
an adjustment to opening retained earnings, even if it elects to use the IAS 19
corridor approach for actuarial gains and losses that arise after first-time adoption
of IFRS. That is, an entity may reset any corridor recognized under previous GAAP
to zero.
II. Restate all defined benefit plans under IAS 19 since the inception of those plans
and defer the restated cumulative actuarial gains and losses.
Survey Results for Item 3
Schwarz, Elan and MediGene applied option I by recognizing cumulative
actuarial gains and losses as an adjustment to opening retained earnings. Evotec,

Sygnis and Shire did not apply this option since they have used defined contribution
plan. World of Medicine did not take this option and did not discuss this item. In
conclusion, for item 3, no obvious pattern has been observed here since three
companies have used defined contribution plan. However, three out of the rest four
companies selected option I. Even though MediGene’s discussion is not very clear, it
doesn’t affect the conclusion that selecting option I serve these companies best.
Excerpts from option I adopters:
Schwarz–from 2005 Annual Report page39
“Employee benefits (IFRS 1.20): All actuarial gains and losses exceeding the 10%
corridor of the higher value of the present value of the pension liabilities and the plan
assets as per 1 January 2004 were fully set off against employee benefits, leaving no
actuarial gains and losses unrecognized in shareholders’ equity.

P118: As

mentioned above, the SCHWARZ PHARMA Group has opted to use the exemption
provisions under IFRS 1 as regards pensions and has set off all unrealized actuarial
gains and losses against pension provisions (Employee benefits)”.
Elan –from 2005 Annual Report page156
“Employee benefits: The corridor method has been applied retrospectively and the
cumulative actuarial gains and losses from the date of inception of our defined benefit
pension plans have been split into a recognized portion and an unrecognized portion
and the recognized portion has been adjusted against retained loss in the opening
balance sheet”.
MediGene–from 2005 Annual Report page63
“As at December 31, 2004, no actuarial gains or losses were reported due to the use
made of the relief option in accordance with IFRS 1. Actuarial gains and losses
arising from experience adjustment and changes in actuarial assumption are posted
to income over the employees expected average remaining working lives”.

1.3 Item 4: IAS 21 Cumulative (foreign) translation differences
An entity may elect to:

I. Recognize all translation adjustments arising on the translation of the financial
statements of foreign entities in accumulated profits or losses at the opening IFRS
balance sheet date. Similar to the effect of Item 3 discussed previously, an entity may
elect to reset the translation reserve included in equity under previous GAAP to zero.
If the entity elects this exemption, the gain or loss on subsequent disposal of the
foreign entity will be adjusted only by those accumulated translation adjustments
arising after the opening IFRS balance sheet date.
II. Restate the translation reserve for all foreign entities since they were acquired or
created.
Survey Results for Item 4
Shire, MediGene, and Sygnis chose this exemption: the cumulative translation
reserve reset to zero. The other four companies did not take this option. There is no
obvious pattern observed for this item. Given the fact observed from Table 4, these
non-option I adopters have been experiencing big losses on this item for several years
in a row, I boldly surmise that since 2004, the first year in which companies started to
convert to IFRS, companies, without relative experience to rely on, inevitably acted
conservatively.
Excerpts from option I adopters:
Shire–from 2005 Annual Report page102
“The Group has elected to set the previously accumulated cumulative translation
differences arising on the translation and consolidation of results of foreign
operations and balance sheets denominated in foreign currencies to zero at January 1,
2004. This exemption has been applied to all subsidiaries in accordance with IFRS
1”.
MediGene–from 2005 Annual Report page55
“IFRS 1 allows companies to apply the standard IAS 21 (the effects of changes in
Foreign Exchange rates) prospectively. This means that it is assumed that all of the
accumulated currency exchange gains and losses reported according to US-GAAP
before the transition date are valued at zero as at the date of transition to IFRS. And

that currency exchange differences which arise after the transition date must be
reported separately in the balance sheet for each foreign subsidiary. The differences
that emerge are set at zero at the date of transition”.
Sygnis–from 2005 Annual Report page32
“The company used the option of IFRS 1.22, which allows the accumulated foreign
currency exchange differences from foreign operations to be set at zero in the opening
balance sheet”.
Discussions for non-option I adopters:
Elan
Elan did not take option I for this item because U.S. dollars is the functional
currency for the parent company and the majority of the group companies. Below is
an excerpt regarding this item taken from Elan 2005 IFRS annual report page80:
“Financial Statements are presented in U.S. dollars rounded to the nearest
million, being the functional currency of the parent company and the majority of
the group companies”.
Even though in 2005 Elan IFRS Annual Report (page74), in stockholders’ equity,
this item is a big loss (-$15.6 million). However, there is a decreasing pattern in this
item from 2005 to 2008; they are -$15.6 million, -$11.7 million, -$11.0 million, and
-$11.0 million respectively.
Evotec
Through reading financial reports from 2004 to 2008, I found the cumulative
foreign currency translation item for 2005 to be € –35,856,000, which is carried over
and this loss is getting bigger.
Schwarz
Schwarz also did not take option I. However, it is interesting to see that during
2005, this item is decreased dramatically from €-61,829,000 to €-861,000. The exhibit
below is taken from Schwarz 2005 Annual Report to show this dramatic change.
［Insert Exhibit 1 here］
］

World of Medicine
No pattern is observed for this item through financial statements from 2004 to
2008. Table 4 summarizes the cumulative translation differences from non-option I
adopters.
［Insert Table 4 here］
］

1.4 Item 8: IFRS 2 Share-based payment transactions
An entity may choose:
I-1. Not to apply IFRS 2 to any equity instruments those were granted before
November 7, 2002.
I-2. Not to apply IFRS 2 to any equity instruments that were granted after November
7, 2002 and vested before the date of transition, but only if the company has
previously disclosed publicly the fair value of the instruments, determined at the
measurement date.
II. To apply IFRS 2 to a liability relating to a cash-settled share-based payment that
was settled prior to the date of transition to IFRS.
Survey Results for Item 8
Sygnis and World of Medicine did not provide such discussions. All other
companies have chosen the option I, which is not to apply IFRS 2 to any equity
instruments that were granted before November 7, 2002, or that were granted after
that date and vested before the date of transition. In conclusion, except that two
companies did not provide such discussions, the rest of five companies selected
option 1. Thus it is safe to say that option I serves these companies the best.
Excerpts from option I adopters:
Evotec–from 2005 Annual Report page69
“IFRS 2, only stock options, which were granted after 7 November and not vested on
31 December 2005, are included in the fair value calculation”.
Elan–from 2005 annual report page156
“Share-based payments: IFRS 2 has been applied retrospectively to those options that

were issued after 7 November 2002 and had not vested by 1 January 2005”.
Schwarz–from 2005 Annual Report page39
“Stock option programs prior to 7 November 2002 and those granted after 7
November 2002 that were already fully exercisable at the time of the opening balance
sheet, were not taken into consideration in preparing the opening balance sheet”.
MediGene–from 2005 Annual Report page55
“The reporting of share-based instruments that were issued before November 7, 2002
is waived”.
Shire–from 2005 Annual Report page102
“The Group has elected to apply the share-based payment exemption. It applied IFRS
2 from January 1, 2004 to those options that were issued after November 7, 2002 but
that have not vested by January 1, 2005”.

2. Reconciliation of Key Accounting Differences
IFRS 1 also requires that the first IFRS financial statements include a reconciliation
of:
(1) Equity from U.S. GAAP to IFRS at the transition date and at the end of the latest
period presented in the company’s most recent annual financial statements under U.S.
GAAP;
(2) Net profit from U.S. GAAP to IFRS for the last period in the company’s most
recent annual financial statements under U.S. GAAP.
The reconciliation information required by IFRS 1 and included in a
reconciliation table usually indicates how equity and net profit from U.S. GAAP get
reconciled to IFRS. The reconciliation disclosures from the eight companies are
summarized in Tables 5 to 8. Specific items in reconciliation disclosures are listed in
an attempt to find what the key items are. A summary of major items in reconciliation
disclosures from the eight companies and the effects of IFRS transition on financial
ratios are also included in Table 9 and Table 10 in this section.
I found that IFRS adoption results in lower net income and higher shareholders’
equity than U.S. GAAP for our sampled companies. The mean (median) differences
between U.S. GAAP and IFRS net income and shareholders’ equity are -59.34% and
15.07% respectively (-0.63% and 3.65% respectively). Elaine, Lin, and Yang (2008)
used 75 European companies cross-listed in the U.S., but found that IFRS provided
higher (lower) net income (shareholders’ equity) than U.S. GAAP. They find that the
mean (median) accounting differences between U.S. GAAP and IFRS net income and
shareholders’ equity are 2.11% and -11.64%, respectively (1.40% and -1.18%). I used
the same calculation method, but my results were quite different from theirs. It
probably could be attributed to following facts: 1. Small sample size. 2. Different
transition date (2004) 3. Seven out of eight companies are experiencing big losses,
which could have something to do with the lower net income under IFRS. In these
IFRS financial statements, I did not observe any obvious national identities, as Ernst
&Young (2006) mentioned that IFRS financial statements retain their national identity.

This is probably because the majority of the companies are from Germany and
because all these sampled companies unanimously used U.S. GAAP before
converting to IFRS. Table 5 below presents net incomes of eight companies under
both U.S.GAAP and IFRS
［Insert Table 5 here］
］

Table 6 summarizes specific items and their proportions to the IFRS Net Income in
reconciliation table. No obvious pattern was observed from the following tables and
these specific items and their proportion vary significantly from company to company
even though they belong to the same industry.
［Insert Table 6 here］
］
Table 7 presents stockholders’ equities of eight companies under both U.S. GAAP and
IFRS.
［Insert Table 7 here］
］

Table 8 summarizes specific items and their proportions to IFRS Stockholders’ Equity
(SE) in the Reconciliation Table. No obvious pattern was observed from the following
tables and these specific items and their proportions vary significantly from company
to company even though they belong to the same industry.
［Insert Table 8 here］
］
Here I have summarized the relatively major items in the reconciliation
disclosures of these companies in Table 9 and have included excerpts on these items.
［Insert Table 9 here］
］

Elan
Excerpts from 2005 Elan IFRS Annual Report page153
Financial instrument-We have adopted IAS 32 and IAS 39 effective 1 January 2005,
which eliminates many of the investment related differences with our U.S. GAAP
results. The principal remaining differences from 2005 onwards relate to the different
carrying values for some of our investments under IFRS as compared to U.S GAAP.

The definition of a derivative instrument under U.S. GAAP is similar to the IFRS
definition with the result that the number of derivatives recorded at fair value through
the income statement will be similar for both GAAPs. However, under U.S. GAAP,
certain non-derivative investments, principally equity investments in private entities,
are not marked-to-market through the balance sheet, whereas all non-derivative
investments are marked-to-market through the balance sheet under IFRS with fair
value changes taken through the fair value reserve.
Revenue recognition-There are different rules under IFRS and U.S. GAAP in relation
to the recognition of revenue arising under contracts which include multiple
arrangements such as the sale of a product and related R&D or manufacturing
arrangements, although the revenue recognized will be the same under both IFRS and
U.S. GAAP over the life of the contract, the different requirements can result in
differences in the timing of revenue recognition.

Schwarz
Under U.S. GAAP, Schwarz used average and LIFO method for inventory valuation.
Under IFRS, only average method was used since LIFO is prohibited by IFRS, which
is the primary cause of the reconciliation differences in the inventory accounts.
Excerpt–from 2005 Schwarz Annual Report page40
Under U.S. GAAP, Inventories are stated at the lower of cost or market. Cost is
generally determined in accordance with the average cost method. Certain foreign
companies determine cost using the last-in, first-out method.
Employee benefits-As mentioned above, the SCHWARZ PHARMA Group has opted to
use the exemption provisions under IFRS 1 as regards pensions and has set off all
unrealized actuarial gains and losses against pension provisions (Employee benefits).

Evotec
Excerpts from Evotec 2005 IFRS Annual Report page60
Impairment (goodwill) – under U.S. GAAP impairment is determined by comparing
the value of the cash generating unit (reporting unit) to which goodwill is attributed

using after tax cash flows discounted at an after tax discount rate, to the fair value of
the assets of that reporting unit. Under IFRS no fair value adjustments are made and
pre-tax cash flows and pre-tax discount rates are used.
Impairment (property, plant and equipment) – under U.S. GAAP, where there is an
indication of an impairment of a fixed asset, the impairment is calculated by
determining the value of the asset to the business using non-discounted cash flows
and comparing this to the carrying value. Under IFRS a similar method to that of
goodwill impairment is used. Asset impairments under IFRS may be reversed if
conditions change.

Sygnis
Sygnis sold its core business, bioinformatics unit in 2005. Adjustment of
severance provision is the only item in the reconciliation table.
Excerpts from Sygnis 2005 Annual Report page31:
Adjustment of severance-Under US-GAAP, severance provision for employees are
accounted for on a pro-rata basis if the term between the termination and the actual
ending of the employment is longer than usual (normally more than three months),
under IFRS such a liability is immediately accounted for at the total amount. This
effect reduced equity in the opening balance as of April, 2004 by € 260 thousand,
which was however counterbalanced by the counter effect in fiscal year 2005,
however, the same issue resulted in a reduction of equity of € 55 thousand as of March
31, 2005.

World of Medicine
Excerpts from World of Medicine 2005 Annual Report page57
Deferred tax adjustment-IFRS and USGP differ from each other regarding the
accounting of deferred taxes in that, according to IFRS, deferred taxes are always
shown as non-current balance sheet items.
The changes to balance sheet items between IFRS and USGP in the opening balance
that led to a €179 difference in shareholder equity primarily due to the adjustment of

budget horizon for the calculation of tax deferrals to losses carried forward.

The effects of IFRS transition on financial ratios
The key financial ratios under both U.S. GAAP and IFRS from four companies are
compared and summarized in Table 10 in an attempt to have better understanding on
the effects of IFRS transition on financial ratios. These financial ratios are
representative of important aspects of financial status which include liquidity,
profitability, activity, and financial leverage. Table 10 below summarizes the effects of
IFRS transition on financial ratios
［Insert Table 10 here］
］

For liquidity ratios, the current ratio is theoretically increased after IFRS
transition because deferred income tax is removed from current liabilities. This result
was observed in the results, but I did not discuss deferred income tax here since this
complex item is subject to regulations of the nations in which the companies operate.
For profitability ratio, the return on assets should theoretically vary with the
changes on net incomes and assets. The results show that the ratios unanimously
become higher. This could be due to small size or coincidence.
For activity ratio, asset turnover is theoretically lower because sales are usually
the same and assets increase after IFRS transition. The results show that ratios of
three companies become lower and only one ratio becomes higher
For leverage ratio, it should theoretically be lower (higher) as net income
becomes higher (lower) after IFRS transition. The results here do not show this
correlation, but show that the ratios unanimously become lower. Again, it could be
due to small sample size.

3. Accounting Choices
The first-time adoption of IFRS also presents companies opportunity to change and
reevaluate their accounting policies. IFRS allows companies to choose from a number of
alternative accounting treatments—for example, the reclassification of interest income
into operating activity or investing activity etc. Table 11 below summarizes the
accounting choices provided by IFRS and the choices made by the surveyed
pharmaceutical companies. A discussion follows Table 11.
［Insert Table 11 here］
］
Discussion for accounting choices
IAS 1, Presentation of Financial Statements, provides two options to classify
expenses under Income Statement by function or by nature. All companies classify
expenses by function as reported under U.S. GAAP.
IAS 7, Cash Flow Statement, permits either indirect or direct methods to prepare the
statement. The indirect method has been uniformly applied by all of the companies. IAS
7 also allows optional choices on the activity classification for the interest expense,
interest income, and dividend income in operating, investing, or financing activities.
IAS 2, Valuation of Inventories, allows two methods: FIFO or average. Because
inventory is not material to GPC Biotech, there is no discussion about this item. There is
also no discussion on this item for MediGene and Sygnis. Evotec and World of Medicine
have followed their previous U.S. GAAP practices by using the average method.
Schwarz was the only company that used LIFO and average under U.S. GAAP and
selected only the average method for IFRS reporting.
IAS 16, Property, Plant and Equipment, allows for either revaluation or cost
valuation methods. None of these companies chose the revaluation method based on the
fair value model. Like U.S. GAAP, IFRS also allows choices for depreciation methods.
All firms have uniformly chosen the straight line method.
IAS 19, Employee Benefits (on actuarial gains/losses), permits immediate
recognition of actuarial gains/losses to equity or the corridor method, which is
commonly used under U.S. GAAP. Elan and Schwarz have followed their previous U.S.

GAAP practices by using the corridor method. GPC Biotech, Evotec and Shire used the
defined contribution plan. MediGene chose the immediate recognition approach. Sygnis
and World of Medicine did not provide such discussions.
I also surveyed how firms apply the exchange rates per IAS 21, The Effects of
Changes in Foreign Exchange Rates, to measure various financial statements. Except
GPC Biotech, which used spot rate of transaction date for its income statement, all of the
other surveyed companies reported period-end rates for their balance sheet and average
rates for their income statement. None of the eight companies disclosed the use of
exchange rates for their statements of cash flow.
Finally, I surveyed the option pricing model used for IFRS 2, Share-Based
Payments/Stock Options. Except for MediGene which used the binomial model, all other
companies used Black-Scholes option-pricing model. An excerpt for this item is presented
below to explain why MediGene chose to use the binomial model.
Excerpt -- from MediGene 2005 Annual Report page62:
The fair values of the options that MediGene grants in return for employees work
performance are reported as expenses. The instruments are valued with the help of the
binomial model instead of the Black Scholes method that was used in the previous years.
The latter can not be used under IFRS because it doesn't portray the fair value correctly.
The binomial model takes account of, among other things, vesting periods, hurdle rate,
volatility of the underlying value and interest rates.

4. Important Accounting Policies
Since the pharmaceutical industry differs from other industries in the areas of
research and development (R&D) and revenue recognition, I have analyzed these two
areas separately.
4.1 Revenue recognition
Under IFRS, rules for revenue recognition are more general compared with those
under U.S. GAAP. According to IAS 11, in general, revenues are recognized when it is
probable that the company will receive economic benefit and the amount of revenue can
be reliably determined. In addition, the main risks and opportunities connected with the
ownership of sold products must have been transferred to the buyer. Table 12 below
presents revenue figures of seven companies from both U.S. GAAP and IFRS
［Insert Table 12 here］
］
Elan and GPC Biotech are the only two companies that have different revenue figures
under U.S. GAAP and IFRS. Excerpts on revenue are taken from their annual reports to
explain why their revenue figures are different under U.S. GAAP and IFRS.
Excerpts on revenue from Elan and GPC Biotech:
Elan –from 2005 IFRS Annual report page154
There are different rules under IFRS and USGP in relation to the recognition of revenue
arising under contracts which include multiple arrangements such as the sale of a
product and related R&D or manufacturing arrangements, although the revenue
recognized will be the same under both IFRS and USGP over the life of the contract, the
different requirements can result in differences in the timing of revenue recognition.
GPC Biotech: the only difference in revenue description between IFRS and U.S. GAAP
is grant revenue.
Excerpt from 2007 IFRS Annual report Page48:
Grants from governmental agencies for the support of specific research and development
projects are recorded as other income to the extent the related expenses have been
incurred and billed in accordance with the terms of the grant.

4.2 Research and development (R&D) cost
Development costs are capitalized as an intangible asset if all of the following criteria
are met [IAS 38R.57]:
a) The technical feasibility of completing the asset so that it will be available for use or
sale;
b) The intention to complete the asset and use or sell it;
c) The ability to use or sell the asset;
d) The asset will generate probable future economic benefits and demonstrate the
existence of a market or the usefulness of the asset if it is to be used internally;
e) The availability of adequate technical, financial and other resources to complete the
development and to use or sell it; and
f) The ability to measure reliably the expenditure attributable to the intangible asset.
For this R&D part, I have summarized accounting treatments for R&D expenditures
from PWC and KPMG publications. I also have summarized the accounting difference in
R&D and intangible assets from U.S. GAAP to IFRS for these pharmaceutical companies.
Below is a summary of accounting treatments for R&D expenditures from PWC and
KPMG publications.
U.S.GAAP
Similarity

Difference

IFRS

Research costs are expensed as incurred under both accounting models.
With very limited exceptions, US
GAAP prohibits the capitalization of
development costs.
In the area of software development
costs, US GAAP provides different
guidance depending on whether the
software is for internal use or for sale.

The recognition and measurement of
intangible assets could differ significantly
under IFRS.
Development costs under IFRS are
capitalized if certain criteria are met. In the
area of software development costs, The
principles surrounding capitalization under
IFRS, by comparison, are the same whether
the internally generated intangible is being
developed for internal use or for sale.

Table 13 below presents accounting difference in R&D and intangible asset from U.S.
GAAP to IFRS. After 1/1/2004, all companies have expensed development costs as

incurred, except Evotec which met the criteria and capitalized as intangible asset. Most
companies have not capitalized development costs since IFRS took effect in 2005. After
converting to IFRS, R&D tends to decrease the mean and median by -3% and -0.3%
respectively while intangible assets tend to increase the mean and median by 25% and 6%
respectively.
［Insert Table 13 here］
］

5. A Brief Discussion of Agency Theory in Explaining Accounting Choices
The choice made at the first time adoption of IFRS can have a significant impact on
financial statements and strategy implications. Companies can benefit from a fresh start
by choosing optional exemptions (Cormier, Demaria, Lapointe-Antunes & Teller, 2008).
Cazavan-Jeny & Jeanjean (2007), in their paper, examine the determinants of
management choices regarding IFRS transition. According to Cazavan-Jeny & Jeanjean
(2007), the impact of a transition to IFRS on key items is relatively limited due to the
companies’ accounting policies. The difference between national GAAP and IFRS usually
comes from mandatory adjustments and optional exemptions. The optional exemptions
allowed by IFRS 1 enable firms to offset the impact of mandatory adjustments required
by IFRS 1 (Cazavan-Jeny & Jeanjean, 2007). Their results are very interesting as they
show that companies are making accounting policy choices that can be considered
opportunistic while financial reporting is supposed to be more transparent. Managers pay
attention to the published figures because those figures can affect their bonus and the
firm’s competitive position.
Their research hypotheses are formulated based on agency theories and signaling
theories, which have significant impacts on accounting choices. The hypotheses are that
optional exemptions are used to minimize the effect of mandatory adjustments on equity
and that Firms choose the options that will enable them to reduce their apparent leverage
(Cazavan-Jeny & Jeanjean, 2007).

6. Conclusion
It has been a growing trend to use a set of high quality global accounting standards
that could be applied by companies and understood by investors around the world. Today,
more than 100 countries around the world require or permit IFRS reporting. Proposed
voluntary application of IFRS will be permitted for some U.S. registrants at fiscal years
ending after December 15, 2009 according to SEC’s proposed roadmap.
This study surveys leading European Union pharmaceutical companies using U.S.
GAAP prior to using IFRS to identify first time IFRS adoption practices and choices for
accounting policies under IFRS. The research tools include SEC EDGAR Company
Search, Business Database: Financial Markets and Services, and Net Advantage.
Survey results are analyzed into three parts in this thesis. First, I looked at the four
most commonly used IFRS 1 optional exemptions at transition date: IFRS 3R, business
combinations, IAS 19, employee benefits, IAS 21, cumulative translation differences, and
IFRS 2, share-based payments. Second, I analyzed the reconciliations of equity and net
profit between U.S. GAAP and IFRS. I found that IFRS adoption results in lower net
income and higher shareholders’ equity than U.S. GAAP for my sampled companies. By
comparing the several financial ratios under U.S. GAAP and IFRS, I found that under
IFRS, current ratio and return on assets increases, asset turnover tends to decrease and
debt to equity ratio decreases. However, these results should be interpreted with caution
because of the small sample used and the sample’s nationality (mostly Germany). Third, I
analyzed accounting choices under IFRS. IFRS allows companies to choose from a
number of alternative accounting treatments. All the surveyed companies made similar
accounting choices. The common choices were to classify expenses by function, keep the
cost method and straight-line depreciation method for property, plant, and equipment, and
to continue using the indirect method to prepare cash flow statement as reported under
U.S. GAAP. All these companies use either FIFO or average method for valuation of
inventory since LIFO is forbade by IFRS. Six out of eight companies have the same
revenue figures under U.S. GAAP and IFRS and all of these companies have different
figures for R&D and intangible asset items even though seven out of eight kept expensing

R&D items. I also found it interesting that when converting to IFRS, R&D tends to
decrease and intangible assets tend to increase even though development costs are not
capitalized. Other accounting treatments vary and depend on the specific situation.
The survey results could be valuable for U.S. companies because it provides
benchmark information. It could also provide U.S. companies a cost-effective pathway in
making their reporting choices in the near future.
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8. Tables
Table 1: Company List
Pharmaceutical
company

Transition Date

Country

Elan

1/1/2004

Ireland

GPC Biotech

1/1/2004

Germany

Shire

1/1/2004

England

MediGene AG

1/1/2004

Germany

Evotec

1/1/2004

Germany

Schwarz Pharma AG

1/1/2004

Germany

Sygnis Pharma AG

4/1/2004

Germany

World of Medicine AG

1/1/2004

Germany

Table 2: List of IFRS 1 Optional Exemptions
Item
1
2
3
4
5
6

Standard No.
IFRS 3R
IAS 16, 38, 40
IAS 19
IAS 21
IAS 32
IAS 27, 28, 31

7
8
9

IAS 39
IFRS 2
IFRS 4

10

IFRIC 1

11
12

IFRIC 4
IAS 39

13
14
15

IFRIC 12
IAS 23
IAS 27R

Title
Business combinations
Fair value or revaluation as deemed cost
Employee benefits (on actuarial gains and losses)
Cumulative (foreign) translation differences
Compound financial instruments
Assets and liabilities of subsidiaries, associates and joint
ventures
Designation of previously recognized financial instruments
Share-based payment transactions
Insurance contracts
Changes in existing decommissioning, restoration, and
similar liabilities included in the cost of property, plant and
equipment
Leases
Fair value measurement of financial assets and financial
liabilities
Service concession arrangements
Borrowing costs
Investments in subsidiaries, jointly controlled entities and
associates

Table 3: Summary of Elected Optional Exemption
Item Standard

Title

Elan Shire MediGene Evotec Schwarz Sygnis

World of
Medicine

1

IFRS 3R

Business combinations

I

I

I

II

I

II

I

3

IAS 19

Employee benefits

I

N/A

I

N/A

I

N/A

II

4

IAS 21

Cumulative translation
differences

II

I

I

II

II

I

II

8

IFRS 2

Share-based payment
transactions

I

I

I

I

I

N/A

N/A

I: Not to retrospectively apply the standard before the date of transition
II: Retrospectively apply the standard before the date of transition
N/A: Not Applicable
Item 3 can not be applied on Shire, Evotec and Sygnis since these three companies have used defined contribution plan.
Item 8 can not be applied on Sygnis and World of Medicine since these two companies don’t have share-based payment transactions.

Exhibit 1: Schwarz: other comprehensive income (loss) from 2005 Annual
Report page 89
Currency Translation
Other Comprehensive Income
Differences
(Loss)
Status on
(61,829)
(61,829)
1/1/2005
Change
60,968
60,968
Status on
(861)
(861)
31/12/2005

Table 4 Summary of Currency Translation Difference

Elan (in million $)
Evotec (in thousands €)
Schwarz (in thousands €)
World of Medicine (in thousands € )

cumulative currency translation differences
1/1/2004 12/31/2004 12/31/2005 12/31/2006 12/31/2007 12/31/2008
-12.2
-12.9
-15.6
-11.7
-11
-11
-40,046
-39,005
-35,856
-33,956
-42,827
-38,835
-31,348
-61,829
-861
-51,577
-4,428
N/A
67
-106
-87
-8
-521
-267

Table 5: Accounting Difference in Net Income (NI)
Company in year 2004
Elan (millions $)
GPCB 1 (2007 T€2 )
Shire (T$3)
MediGene (T€)
Evotec (T€)
Schwarz (T€)
Sygnis (T€)
World of Medicine
(T€)
Mean
Median

NI-IFRS
(1)
-379.5
-73,595
96,509
-12,666
-77,812
-835
-12,945

NI-USGP
(2)
-394.7
-69,245
269,007
-12,306
-84,203
1,844
-13,150

Difference
(1)-(2)
15.2
-4,350
-172,498
-360
6,391
-2,679
205

Percentages
[(1)-(2)]/(1)
4.00%
-5.90%
-179%4
-2.84%
8.20%
-320%5
1.58%

-7,922

-6,396

-1,526

19.26%
-59.34%
-0.63%

1. GPCB’s financial figures under both USGP and IFRS is found in 2007’s financial
statements instead of 2004
2. T€: figures in thousands of euros except for percentages
3. T$: figures in thousands of dollars
4. -179%*
*: the 2004 IFRS income statement of Shire presents much higher R&D (210,974)
and selling general and administrative expenses (718,890) than those (196,265 and 516,645
respectively) of USGP, leading to lower net income under IFRS than USGP.
5. -320%*:
*: the 2004 IFRS income statement of Schwarz presents much lower other income
from investment (101T€) than that (17,890 T€) of USGP, leading to lower net income under
IFRS than USGP.

Table 6: Specific items and their proportions to the IFRS Net Income in
reconciliation table 1
Reconciliation item in Net
income/companies
Intangible assets
Financial
instruments/non-consolidated
Revenue recognition
Acquired product rights and
finance charges write off
Share-based payments
Other
General and administrative
expenses
Interest income and
expenditures
Costs of revenue
Research and development
expense
Amortization of intangible
asset
Impairment of goodwill
Impairment of tangible asset
Net loss from equity
investments
Deferred tax benefit
Executive stock options
programs
Inventories
Property, plant and
equipment
Other non-current provisions
Employee benefits
Adjustment of severance
provision
Deferred tax adjustment due
to adjusted budget horizon

Elan

GPCB3

Shire4

MediGene

Evotec

3%

0.10%

0.10%

0.03%

Schwarz

Sygnis

World of
Medicine

6%2
17%
12%
3%
4%
6%

0.20%
0.40%
0.06%
14%
6%
0.30%
7%

62%
372%
160%
14%
71%
99%
1.60%

1. Reconciliation Table usually indicates how equity and net profit from U.S.GAAP get reconciled to IFRS
2. The percentage is calculated by dividing the specific reconciliation item by company’s IFRS Net income.
3. The reconciliation item of GPCB is not available.
4. Shire only provides reconciliation between UK GAAP and IFRS instead of U.S GAAP and IFRS.

7%

Table 7: Accounting Difference in Stockholders Equity (SE)
SE-IFRS
SE-USGP
Difference
Company
(1)
(2)
(1) - (2)
Elan (million $)
538
205
333
GPCB (2007 T€)
44,119
38,603
5,516
Shire (T$) 4,244,932
2,250,653
1,994,279
MediGene (T€)
29,249
29,220
29
Evotec (T€)
110,508
102,498
8010
Schwarz (T€)
528,211
528,797
-586
Sygnis (T€)
23,538
23,593
-55
World of Medicine
19,250
20,597
-1,347
(T€)
Mean
Median

Percentages
[(1) - (2)]/(1)
62.00%
12.50%
45.80%
0.10%
7.20%
-0.10%
-0.23%
-6.70%
15.07%
3.65%

Table 8: Specific Items and their proportions to the IFRS SE in Reconciliation Table1
Reconciliation item in
equity/companies
Intangible assets
Financial
instruments/non-consolidated
Revenue recognition

GPCB3

Shire4

MediGene

Evotec

Additional pain-in capital

0.40%

2%

Accumulated deficit
Net income recognized directly in
equity
Reserve

4%

6%

Other

Elan

Schwarz

Sygnis

World of
Medicine

45%2
3%
20%
0.20%

3%
0.50%

Inventories

0.20%

Property, plant and equipment

0.01%

Restructuring provisions

0.10%

Other non-current provisions

0.40%

Employee benefits

0.80%

Deferred tax

0.20%

Currency translation differences

0.03%

Minority interests

0.20%

Adjustment of severance provision

0.20%

Net income/loss carried forward

1%

Net income/net loss

8%

1. Reconciliation Table usually indicates how equity and net profit from U.S.GAAP get reconciled to IFRS
2. The percentage is calculated by dividing the specific reconciliation item by company’s IFRS Net equity.
3. The reconciliation item of GPCB is not available.
4. Shire only provides reconciliation between UK GAAP and IFRS instead of U.S GAAP and IFRS.

Table 9: Summary of Major Items in Reconciliation Disclosures

Companies
Elan
GPC Biotech
Shire

Significant reconciliation items for NI and SE
Financial instruments, revenue recognition
No discussion
No discussion

MediGene

Accumulated deficit, net income recognized in equity (no
explanation)

Evotec

Impairment of goodwill, impairment of tangible assets

Schwarz

Employee benefits, inventory

Sygnis

Adjustment of severance provision

World Of Medicine

Deferred tax adjustment

Table 10: The effects of IFRS transition on financial ratios
IFRS

Shire (2005 T $)

Evotec (2004 T€)

GPCB (2007 T€)

Schwarz (2004 T€)

USGP

IFRS

USGP

IFRS

USGP

IFRS

USGP

IFRS

R&D Expenses

Lower R&D

336,217

287,146

13,772

13,490

51,437

50,551

197,667

198,321

NI or OI

Higher profit or
lower loss

-410,843

-177,378

-84,203

-77,812

-69,245

-73,595

19291 OI

15030 OI

Deferred
Income
Tax
makes it lower

1,312,222/965,421
= 1.36

1,245,217/968,940
= 1.29

44,949/20,886
= 2.15

44,869/21,512
= 2.09

69,114/17,603
= 3.93

69,114/17,726
= 3.90

522,115/328,526
= 1.59

484,198/261,398
= 1.85

Profitability Ratio Return on
Assets=Net Income/Assets

Depends Appear
to be higher

-410,843/2,798,240
= -0.15

-177,378/5,227,905
= -0.03

-84,203/138,534
=- 0.61

-77,812/146,544
= -0.53

-69,245/73,386
= -94.49%

-73,595/78,658
= -93.56%

19,291/994,460
= 1.9%

15,030/943,898
= 1.6%

Activity Ratio Asset
turnover=Sales/Assets

Lower

1,599,316/2,798,240
= 0.57

1,599,316/5,227,905
= 0.31

72,730/138,534
= 0.52

72,730/146,544
= 0.50

18,315/73,386
= 0.25

22,252/112,523
= 0.20

946,647/994,460
= 0.95

946,647/943,898
= 1.002

Leverage Ratio
Debt/Equity

Lower

1,008,974/1,789,266
= 0.56

1,144,772/4,083,133
= 0.28

36,524/102,010
= 0.36

36,036/110,508
= 0.33

34,783/38,603
= 0.90

34,539/44,119
= 0.78

465,663/528,797
= 0.88

415,687/528,211
= 0.79

Liquidity:
=CA/CL

Current

Ratio

Note: USGP: U.S. GAAP
Given the availability of some important figures, some data are from different year than 2004.

Table 11: Accounting choices
Elan
IAS 1

Shire

MediGene

Evotec

Schwarz

Sygnis

WM

Presentation of Financial Statements
Expenses Classification 1-Functional 2-Nature

IAS 7

GPCB

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

2

nd

1

nd

1

1

1

1

2

nd

nd

nd

1

nd

nd

nd

nd

nd

nd

nd

nd

nd

nd

nm

nd

nd

2

2,3

nd

2

1

nm

1

nd

2

2

nd

2

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

N/A

N/A

1

N/A

2

nd

nd

Balance Sheet:

1

1

1

1

1

1

1

1

Income Statement

1

3

1

1

1

1

1

1

nd

nd

nd

nd

nd

nd

nd

nd

Y

Y

Y

N

nd

nd

nd

nd

Cash Flow Statement
Method: 1-Indirect 2-Direct
Interest Expense:
1-Operating Activity 2-Financing Activity
Interest Income:
1-Operating Activity 2-Investing Activity
Dividend Income:
1-Operating Activity 2-Investing Activity

IAS 2

Valuation of Inventories (Method)
US-GAAP method 1-FIFO 2-Average 3-LIFO
IFRS: 1-FIFO 2-Average

IAS 16

Property, Plant And Equipment
Valuation Method: 1-Cost 2: Revaluation
Depreciation Method: 1-Straight Line
2-Accelerated Declining 3-SYD

IAS 19

Employee Benefits
Actuarial gains/losses: 1-Immediate Recognition 2-Corridor
Foreign Exchange Rates

IAS 21

1-Period end closing rate 2 Average
3-Spot rate of transaction date

Statement of Cash Flow
IFRS 2

Share-Based Payments/Stock Options
Black-Scholes option-pricing model

Other (be specific)
nd: no discussion provided
N/A: not applicable
nm: The company specified the item is not material

Binomial

Table 12: Summary of Accounting Difference in Revenue Recognition
2004 revenue under
Pharmaceutical
2004 revenue under
USGP(2)
companies
IFRS (1)

[(1)-(2)]/(1)

Elan (millions $)

367

481.7

-31%

GPCB (2007 T€)

18,022

18,315

-1.60%

1,363,207

1,363,207

0

MediGene (T€)

13,138

13,138

0

Evotec (T€)

72,730

72,730

0

Schwarz (T€)

946,647

946,647

0

nd

nd

nd

Shire (T$)

Sygnis (T€)

World of Medicine
30,811
30,811
(T€)
All these data are from 2004 financial statements except GPCB used data from 2007

0

Table 13: Accounting Difference in R & D and Intangible Asset (IA)
R&D-IFRS

R&D-USGP

Difference

Percentages

IA-IFRS

IA-USGP

Difference

Percentages

(1)

(2)

(1)-(2)

[(1)-(2)]/(1)

(1)

(2)

(1)-(2)

[(1)-(2)]/(1)

Company
Elan (million $)

262.6

257.3

5.3

2%

1013

753.7

259.3

26%

GPCB (2007 T€)

50,551

51,437

-886

-2%

6105

164

5,941

97%

Shire (2005*T$)

287,146

336,217

-49,071

-17%

1,394,677

729,304

665,373

48%

MediGene (T €)

15,627

14,701

926

6%

7,020

7,020

0

0%

Evotec (T€)

13,490

13,772

-282

-2%

7,963

7,507

456

6%

Schwarz (T€)

197,667

198,321

-654

-0.3%

199,361

196,189

3,172

2%

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

3,955,455

3,955,455

0

0%

1,858,779

1,858,779

0

0%

Sygnis (T€)
World of Medicine (T€)
Mean
Median

-3%

25%

-0.3%

6%

Note: All these data are from 2004 except for Shire and GPCB
*. relative figures from 2005 are used given the availability of the data under both U.S.GAAP and IFRS

9. Appendix:
This Appendix contains five parts as follows:
9.1－company background
9.2－excerpts on key items from both U.S. GAAP and IFRS
9.3－excerpts on exemptions from Shire, Elan and MediGene
9.4－excerpts on reconciliation from Elan
9.1 Company background
Evotec
Evotec AG is a biotechnology group dedicated to the discovery and development of novel
small molecule drugs through both its own discovery programs and through contract
research partnerships. It was founded on 8th December 1993. The geographical spread of
revenues for the Group continues to be diverse. Europe continues to be the largest market
with 51% of total revenues (2004: 46%), and the US market being second at 37% (2004:
42%). The Group’s overall gross margin for 2005 was 36.3% (2004: 34.1%) with cost of
revenues amounting to € 50.8 m (2004: € 47.9 m). This improvement comes as a result of
a program of cost and efficiency improvements across all divisions together with
changing market demands which have improved the revenue mix. While the US Dollar
continues to be weak and therefore affects the Company’s pricing and gross margin
versus competitors with US based operations, the average US Dollar exchange rate was
the same in 2005 as in 2004, and therefore currency effects have had less of an impact on
the year on year comparisons. In total, currency contributed 0.6% points to the margin
improvement. The Company’s consolidated financial statements of 31 December 2005
are prepared in accordance with International Financial Reporting Standards (IFRS).

GPC Biotech
GPC Biotech is a publicly traded biopharmaceutical company focused on discovering and
developing anticancer drugs and is incorporated in Germany. Its wholly owned U.S.
subsidiary is located in Princeton, New Jersey. The consolidated financial statements of
GPC Biotech AG and its subsidiary have been prepared in accordance with IFRS. Year
2005 is the first year that GPC Biotech converted to IFRS from U.S.GAAP; however it
did not provide IFRS financial statement until 2007, which does not provide first time

adoption practice. The year 2007 turned out to be the most difficult year in the history of
GPC Biotech. In February, the company completed a New Drug Application Submission
for Satraplatin. Unfortunately, in late October 2007, the company announced that
Satraplatin did not demonstrate an improvement in overall survival in the total patient
population enrolled in the SPARC trial.

Shire
Shire Group develops and market products for specialty physicians. The Group focuses
on four therapeutic areas: central nervous system, gastro-intestinal, human genetic
therapies and general products. This is the first year that the Company has presented its
financial statement under IFRS.
Substantially all of the Company’s revenues, expenditures, operating profits or losses and
net assets are attributable to the Research and Development (R&D), manufacture, sale
and distribution of pharmaceutical products within two operating segments:
Pharmaceutical Products and Royalties. 83% (2004: 82%) of total revenues are derived
from product sales, 15% of total revenues are derived from royalties (2004: 17%). All
royalty income falls within the Royalties segment. For the year to December 31, 2005, the
Company’s total revenues increased by 17% to $1,599.3 million, compared to $1,363.2
million in 2004. Net loss for the year to December 31, 2005 was $177.4 million compared
to net income of $96.5 million in 2004. The results for 2005 include a $527.0 million
impairment of the goodwill that arose on the acquisition of BioChem Pharma Inc. (2004:
an impairment of $132.6 million was recorded).

MediGene
MediGene Group was founded in 1994 in Germany. The purpose of the Group is research,
development and commercialization of, in particular, technologies applied in molecular
biology processes and products in the field of drugs, pharmaceutical substances. Year
2005 is the first year that the Company has presented its financial statement under IFRS.
MediGene’s revenue increased by 50% in 2005. The increase results particularly from its
first drug on the market, Eligard, for the treatment of prostate cancer. In June 2005,
MedeGene was honored with the ARC award- The World’s Best Annual Report for its
annual report in 2004.

Elan
Elan Corporation is a neuroscience-based biotechnology company headquartered in
Dublin, Ireland. It was incorporated as a private limited company in Ireland in December
1969 and became a public limited company in January 1984. Its principal research and
development, manufacturing and marketing facilities are located in Ireland, the United
States (U.S.) and the United Kingdom (U.K.). Its business is organized into two business
units: Biopharmaceuticals and EDT. Biopharmaceuticals engages in research,
development and commercial activities and includes our activities in the areas of
autoimmune diseases, neurodegenerative diseases and our specialty business group. EDT
focuses on product development, scale-up and manufacturing to address drug
optimization challenges of the pharmaceutical industry. Prior to the 2004 fiscal year, its
Consolidated Financial Statements had adopted Irish GAAP. Beginning with 2004 fiscal
year, it has adopted U.S. GAAP as the basis for the preparation of Consolidated Financial
Statements. Accordingly, it’s Consolidated Financial Statements on this Form 20-F are
prepared on the basis of U.S. GAAP for all periods presented. It also prepared separate
Consolidated Financial Statements in accordance with IFRS since the year ended
December 31, 2005. Financial Statements are presented in U.S. dollars rounded to the
nearest million, being the functional currency of the parent company and the majority of
the group companies. It has incurred significant losses during the last three fiscal years
and anticipates continuing losses for the foreseeable future.

Schwarz Pharma
The SCHWARZ PHARMA Group is a multinational pharmaceutical enterprise supplying
a broad and diversified range of pharmaceutical products and services, with activities in
research, development, marketing approval, manufacturing, and marketing. Its research
activities are chiefly concentrated in two of its group companies, one in Germany and one
in the USA, while its production sites are located in the USA, Ireland, Germany, and
Poland. It also operates a China-based joint-venture production company in Zhuhai. The
group’s distributors are spread out throughout the USA, Europe, and Asia. 2004 was
particularly marked by advances in clinical development. One highlight certainly was
submitting the applications for market approval with the U.S. and European regulatory
authorities for Neupro® (rotigotine transdermal system). The consolidated financial
statements have been prepared in accordance with IFRS since 2005 as required by
European Union. In fiscal year 2005, the SCHWARZ PHARMA Group achieved sales of

€990.6 million, marking a 4.6% increase over the previous year. The acquisition of the
entire rotigotine rights in July 2005 led to an operating result of €–17.0 million, after
€15.8 million in the previous year, and a net result of €–54.1 million (€–0.8 million).

Sygnis Pharma
It was incorporated in Germany in March 1997. The company originally offered drug
discovery and knowledge management IT solutions and developed information
management software and data integration to improve R&D performance in the life
science industry.

On March 24, 2005, the enlargement of the company’s business

purpose was approved. It now also includes the acquisition, holding, administration and
the sale of investments, especially in the life science and IT market. At the end of fiscal
year 2005, it sold its core business, bioinformatics unit, to BioWisdom Ltd. As a result of
the sale and drastic reduction of workforce, it has also implemented the downsizing of the
management board. Its consolidated financial statements were prepared in accordance
with U.S.GAAP up to and include 2005. As a gear to capital market,

it changed its

accounting in full to IFRS as of April 1 2005, applying IFRS 1 , “First time adoption”

World of Medicine
W.O.M.AG is a supplier of technical equipment for Minimally Invasive Surgery (MIS),
and develops, manufactures and distributes primarily insufflators, pump systems, cameras,
light sources and video documentation systems for MIS, as well as the accessories and
disposable supplies necessary for devices application. It has been the global market leader
in this area for more than 30 years. The aforementioned products from W.O.M Group are
distributed worldwide. The subsidiary W.O.M USA Inc. is responsible for marketing and
sales in North America. The Germen subsidiary exclusively supplies research and
development services for the Group. The consolidated financial statements have been
prepared in accordance with IFRS since 2005 as required by European Union. In 2005, it
minimized dependency on exchange rates in the core business by shifting purchasing
volume to U.S. dollar territory. Its consolidated revenue declined by about 6%. This
decline is attributed to the delayed launch of the new generation of digital camera and the
challenging market environment in Europe.

9.2 Excerpts on key items from both U.S. GAAP and IFRS:
Elan R&D (U.S. GAAP)–from 2005 U.S. GAAP Annual Report page15
R&D costs are expensed as incurred. Acquired in process research and development
arising on business combinations is expensed on acquisition. Costs to acquire intellectual
property, product rights and other similar intangible assets are capitalized and amortized
on a straight-line basis over the estimated useful life of the asset. The method of
amortization chosen best reflects the manner in which individual intangible assets are
consumed.
Elan R&D (IFRS) –from 2005 IFRS Annual Report page85
Expenditure on research activities undertaken with the prospect of gaining new scientific
or technical knowledge and understanding is expensed as incurred. Expenditure on
development activities, whereby research findings are applied to a plan or design for the
production of new or substantially improved products and processes, is expensed when
incurred, unless the criteria for recognition of an internally generated intangible are met.
Regulatory and other uncertainties generally mean that such criteria are not met. To date,
we have not had any development expenditures that have met the criteria for recognition
of an internally generated intangible asset.
GPCB R&D (U.S. GAAP)–from 2005 U.S. GAAP Annual Report page46
Research and development (R&D) expenses include salaries, benefits, and other
headcount related costs; clinical trial and related clinical manufacturing costs; contract
and other outside service fees; employee stock-based compensation expense; and
facilities and overhead costs. R&D expenses consist of independent R&D costs and costs
associated with collaborative R&D and in-licensing arrangements. In addition, we
acquire R&D services from other companies and fund research institutions under
agreements which we can generally terminate at will.
GPCB R&D (IFRS)–from GPCB 2005 IFRS Annual Report page40
In accordance with IAS38, research costs, which are defined as costs of original and
planned research performed to gain new scientific or technical knowledge and
understanding, are expensed as incurred. Development costs are defined as costs
incurred to achieve technical and commercial feasibility. Since regulatory and other
uncertainties inherent in the development of the company’s new products are so high that
the requirements set out in IAS38 are not met, these internal development costs are not
capitalized, but expensed as incurred.

GPCB
Similar part of Revenue Recognition under U.S. GAAP and IFRS–from 2007 IFRS
Annual Report p46 and 2007 U.S. GAAP Annual Report page46
Licensing Arrangements
The Company generally receives non-refundable upfront fees upon signing of a licensing
agreement. These fees generally include licensing fees, technology access fees and
initiation fees. All non-refundable upfront fees received or to be received under these
arrangements are recognized when SAB 104 revenue recognition criteria are met, ratably
over the term of the agreements, as this is the period over which the license is granted or
the Company is substantially and continually involved.
Co-Development Arrangements
Revenue recognized from partners in co-development arrangements is generally based on
a fixed-percentage of agreed upon research, development and commercialization costs
incurred by the Company. Revenue from these co-development arrangements are
recognized on a gross basis as collaboration revenue in the consolidated statement of
operations as the related costs are incurred. If payments are received prior to the activity
having been performed, these amounts are deferred and recognized in future periods
when the co-development costs are incurred.
Milestone Payments
Milestone payments are recognized as revenue when the performance obligations, as
defined in the contracts, are achieved. Performance obligations typically consist of
significant milestones in the life cycle of the related technology or product candidate,
such as initiation of clinical trials, filing for approval with regulatory agencies and
approvals by regulatory agencies. These milestone payments are generally tied to a
specific performance condition and are recognized in full when the performance
obligation is met. The reaching of a milestone is evidenced by a milestone confirmation
letter that is signed and dated by both parties. In the absence of such milestone
confirmation, no milestone revenue is recognized, unless there is other persuasive
evidence that the milestone event has been reached and the milestone fee has been
earned.
Different part of Revenue Recognition:
GPCB Revenue (U.S. GAAP)–from 2007 U.S. GAAP Annual Report page46
Grant revenues from governmental agencies for the support of specific research and
development projects are recorded as revenue to the extent the related expenses have been

incurred and billed in accordance with the terms of the grant.
GPCB Revenue (IFRS)–from 2007 IFRS Annual Report page48
Grants from governmental agencies for the support of specific research and development
projects are recorded as other income to the extent the related expenses have been
incurred and billed in accordance with the terms of the grant.

9.3 Excerpts on exemptions from Shire, Elan and MediGene:
Shire–from 2005 IFRS Annual Report page102
40 Explanation of transition to IFRS
This is the first year that the Company has presented its financial statement under IFRS.
The following disclosures are required in the year of transition. The last financial
statements under UK GAAP were for the year ended December 31, 2004 and the date of
transition to IFRS was therefore January 1, 2004.
Exemptions from full retrospective application -elected by the Group
The Group has elected to apply the following optional exemptions from full retrospective
application.
Business combinations exemption
The Group has applied the business combination exemption in IFRS 1. It has not restated
business combinations that took place prior to the January 1, 2004 transition date in
accordance with IFRS 3, Business Combinations.
Cumulative translation differences exemption
The Group has elected to set the previously accumulated cumulative translation
differences arising on the translation and consolidation of results of foreign operations
and balance sheets denominated in foreign currencies to zero at January 1, 2004. This
exemption has been applied to all subsidiaries in accordance with IFRS 1.
Exemption from restatement of comparatives for IAS 32 and IAS 39
The Group has elected to apply this exemption. It applies UK GAAP rules to derivatives,
financial assets and financial liabilities and to hedging relationships for the 2004
comparative information. The adjustments required for differences between UK GAAP
and IAS 32 and IAS 39 are determined and recognized at January 1, 2005.
Designation of financial assets and financial liabilities exemption
The Group reclassified various equity investments as available-for-sale investments. The
adjustments relating to IAS 32 and IAS 39 are required and determined at the opening
balance sheet date of January 1, 2005 -the IAS 32 and IAS 39 transition date.

Share-based payment transaction exemption
The Group has elected to apply the share-based payment exemption. It applied IFRS 2
from January 1, 2004 to those options that were issued after November 7, 2002 but that
have not vested by January 1, 2005.
Fair value measurement of financial assets or liabilities at initial recognition
The Group has applied the exemption offered by the revision of IAS 39 on the initial
recognition of the financial instruments measured at fair value through the income
statement where there is no active market.
Elan –from 2005 IFRS Annual Report page147
Exemptions under IFRS 1
In accordance with IFRS 1, which establishes the framework for transition to IFRS by a
first-time adopter, we elected to avail ourselves of a number of specified exemptions from
the general principle of retrospective restatement as follows:
(i) Business combinations:
Business combinations undertaken prior to the transition date of 1 January 2004 have not
been subject to restatement and accordingly, goodwill at the transition date is carried
forward at its net book value and is subject to annual impairment testing in accordance
with IAS 36, “Impairment of Assets”
(ii) Employee benefits:
The corridor method has been applied retrospectively and the cumulative actuarial gains
and losses from the date of inception of our defined benefit pension plans have been split
into a recognized portion and an unrecognized portion and the recognized portion has
been adjusted against retained loss in the opening balance sheet.
(iii) Share-based payments:
IFRS 2 has been applied retrospectively to those options that were issued after 7
November 2002 and had not vested by 1 January 2005.
(iv) Financial instruments:
We have adopted IAS 32 and IAS 39 from 1 January 2005, with no restatement of
comparative information. Therefore, financial instruments in the comparative 2004
period continue to be recorded on an Irish GAAP basis. With effect from 1 January 2005,
we reclassified various financial instruments as available-for-sale investments and as
derivatives at fair value through the income statement.

MediGene – from 2005 Annual Report page55
(2) Relief options in IFRS 1 as per the transition date January 1, 2004 are being used
as follows:
Business Combinations:
MediGene AG acquired a company in 2001. MediGene’s management decided that it
would make use of the relief option for corporate mergers provided for under IFRS 1 and
that, consequently, the previous accounting principles for corporate mergers carried out
before the transition date (January 1, 2004) would not be adapted to the new principles.
Foreign currency translation:
IFRS 1 allows companies to apply the standard IAS 21 (the effects of changes in Foreign
Exchange rates) prospectively. This means that it is assumed that all of the accumulated
currency exchange gains and losses reported according to US-GAAP before the transition
date are valued at zero as at the date of transition to IFRS. And that currency exchange
differences which arise after the transition date must be reported separately in the
balance sheet for each foreign subsidiary. The differences that emerge are set at zero at
the date of transition from US-GAAP to IFRS in the item “Net income/expenses recorded
directly in equity” and the retained earnings are reduced accordingly. The retained
earnings are reported in the balance sheet under the item “Accumulated Deficit”.
Compound Financial Instruments:
A compound financial instrument is divided into an equity and borrowings component
only if the borrowings component still exists as at the transition date (January 1, 2004).
These compound financial instruments are portrayed in accordance with IAS32 or IAS 39.
The equity component is produced by the difference between the issue proceeds and the
fair value of the future payment obligations (borrowings component).
Share-based compensation:
Share-based instruments, such as options and convertible bonds issued to employees are
reported in the balance sheet in accordance with IFRS 2. Under this regulation, the
reporting of share-based instruments that were issued before November 7, 2002 is
waived.
No further options in addition to the above are used for the transition from US-GAAP to
the new accounting standard.
Mandatory exemptions
The application of the mandatory exemptions in IFRS 1 did not give rise to any
adjustments.

Schwarz – from 2005 Annual Report page39
The following exemptions from retrospective adjustment were elected pursuant to IFRS 1:
Business combinations (IFRS 1.15): Goodwill from historic acquisitions of companies
measured and carried forward under US GAAP are carried forward in the opening
balance sheet. The balance sheet values as per 1 January 2004 were tested for
impairment pursuant to IAS 36.
Employee benefits (IFRS 1.20): All actuarial gains and losses exceeding the 10%
corridor of the higher value of the present value of the pension liabilities and the plan
assets as per 1 January 2004 were fully set off against employee benefits, leaving no
actuarial gains and losses unrecognized in shareholders’ equity.
Share-based payment transactions (IFRS 1.25B and 1.25C): Stock option programs
granted prior to 7 November 2002, and those granted after 7 November 2002 that were
already fully exercisable at the time of the opening balance sheet, were not taken into
consideration in preparing the opening balance sheet. They will not affect the net result
posted in the consolidated financial statements of the SCHWARZ PHARMA Group in
future. Hence, specifically the first, second, and third trances of the Executive Stock
Option Program 2000 are not taken into account in the group’s
IAS/IFRS consolidated financial statements. However, the effects of the Executive Stock
Option Program 2003 (first and second trances) were and will in future be expensed in
the consolidated financial statements.
9.4 Excerpts on reconciliation –from Elan 2005 IFRS Annual Report page152
Reconciliation from IFRS to U.S. GAAP
The following is reconciliation to net loss and shareholders equity calculated in accordance with U.S.
GAAP:
Net income/ (loss) for the years ended:

Net income/(loss) as stated under IFRS
Adjustments to conform to U.S. GAAP:
(a) Intangible assets
(b) Financial instruments/non-consolidated subsidiaries
(c) Revenue recognition
(d) Convertible notes—fair value on conversion option
(d) Convertible notes—net charge on debt retirement

31 December
2005
$m

31 December
2004
$m

612.3

(379.5)

64.3
8.1
50.8
(1,136.1)
(31.6)

21.8
(63.2)
46.2
—
—

(d) Convertible notes—accretion of discount
(e) Acquired product rights and finance charges write off

12.4
—

—
(12.0)

(f) Share-based payments
Other

36.6
(0.4)

15.1
(23.1)

(383.6)

(394.7)

Net loss as stated under U.S. GAAP
Shareholders’ equity

Shareholders’ equity as stated under IFRS
Adjustments to conform to U.S. GAAP:
(a) Intangible assets
(b) Financial instruments/non-consolidated subsidiaries
(c) Revenue recognition
(d) Convertible notes
Other
Shareholders’ equity as stated under U.S. GAAP

31 December
2005
$m
308.4

31 December
2004
$m
538.0

(177.3)
(1.4)
(56.4)
(46.4)

(241.6)
14.7
(107.2)
—

(10.0)

1.1

16.9

205.0

The principal differences between IFRS as adopted in the EU and U.S. GAAP, as they
apply to our financial statements, are as follows:
a. Intangible assets
The carrying value of our intangible assets is higher under IFRS than under U.S. GAAP
because of differences in our historical Irish GAAP accounting for business combinations
which have carried into our IFRS financial statements as part of the transitional
arrangements. This in turn gives rise to a higher amortization charge under IFRS than
under U.S. GAAP. Additionally, higher carrying values under IFRS will result in higher
intangible impairment charges if the fair value of the related intangibles declines
post-acquisition.
The principal reason for a higher carrying value of intangibles under IFRS is that under
U.S. GAAP, the fair value of acquired IPR&D is expensed upon acquisition, whereas
under Irish GAAP as carried into IFRS these amounts are capitalized as acquired IPR&D.
Additionally, under U.S. GAAP, our acquisition of Dura was accounted for under the
pooling-of-interests method, whereas under Irish GAAP and now IFRS this transaction
was accounted for using the purchase method. As a result, under U.S. GAAP, the assets
and liabilities of Dura were recorded at their historical carrying amounts and no goodwill
arose from the merger of Dura and Elan, whereas under IFRS the assets and liabilities of
Dura were recorded based on their fair values at the date of acquisition, and the excess of
the purchase price over the fair value of assets acquired was allocated to goodwill. Also, a

number of differences arise in the manner in which goodwill was previously written off
when businesses were sold under Irish GAAP and U.S. GAAP. As we did not restate our
historical business combinations in accordance with IFRS 3, “Business Combinations”, as
permitted by IFRS 1, these differences remain in effect between U.S. GAAP and IFRS.
b. Financial instruments/non-consolidated subsidiaries
Effective 1 January 2005
We have adopted IAS 32 and IAS 39 effective 1 January 2005, which eliminates many of
the investment related differences with our U.S. GAAP results. The principal remaining
differences from 2005 onwards relate to the different carrying values for some of our
investments under IFRS as compared to U.S GAAP. The definition of a derivative
instrument under U.S. GAAP is similar to the IFRS definition with the result that the
number of derivatives recorded at fair value through the income statement will be similar
for both GAAPs. However, under U.S. GAAP, certain non-derivative investments,
principally equity investments in private entities, are not marked-to-market through the
balance sheet, whereas all non-derivative investments are marked-to-market through the
balance sheet under IFRS with fair value changes taken through the fair value reserve.
Prior to 1 January 2005
Prior to 1 January 2005, our investments and derivatives were accounted for on an Irish
GAAP basis, which resulted in a significant number of differences from U.S. GAAP.
These are detailed below. Derivative instruments were marked-to-market through the
income statement under both Irish GAAP and U.S. GAAP. However,
The definition of a derivative instrument is significantly broader under U.S. GAAP than
under Irish GAAP, with the result that more derivatives were marked-to-market through
the income statement under U.S. GAAP than under Irish GAAP. Additionally, under U.S.
GAAP, quoted common stock and certain debt instruments are marked-to-market on the
balance sheet, but were not marked-to-market under Irish GAAP, and, consequently,
shareholders’ equity differences arose. These differences will remain in effect as the
carrying basis of certain investments under IFRS is derived from the Irish GAAP basis.
Under Irish GAAP, when a convertible instrument is exercised and converted into
common shares of the issuer, the common shares acquired as a result are recorded at their
fair value on the date of conversion, with any excess over the carrying value of the
convertible instrument recorded as a gain. Under U.S. GAAP, no gain is recorded upon
conversion. As a result, there is a different historic cost basis for converted investments.
Under IFRS, EPIL and EPIL II have been consolidated as subsidiaries of Elan, with the

loan notes issued by each entity being recorded as a liability and the related interest
charges expensed through the income statement. Under U.S. GAAP, both entities were no
consolidated subsidiaries through the date of repayment of their loan notes (March 2001
and June 2004, respectively), as we had effected a true legal sale of a portfolio of
investments to each entity and had not retained control over the transferred assets.
Accordingly, the transfer of investments to each entity was treated as a sale of the assets
at fair value under U.S. GAAP, and the related loan notes were not included as a liability.
As a consequence, we did not record an expense for the related interest charges under U.S.
GAAP. In addition, the timing and amount of charges related to impairments of the
investments transferred to these entities differed under IFRS and U.S. GAAP, since under
IFRS each investment was assessed for impairment individually at each balance sheet
date, whereas under U.S. GAAP we recorded provisions under our guarantee agreements
with the note holders based upon the difference at each balance sheet date between the
fair value of the total assets of each entity and its total liabilities.
c. Revenue recognition
There are different rules under IFRS and U.S. GAAP in relation to the recognition of
revenue arising under contracts which include multiple arrangements such as the sale of a
product and related R&D or manufacturing arrangements. Although the revenue
recognized will be the same under both IFRS and U.S. GAAP over the life of the contract,
the different requirements can result in differences in the timing of revenue recognition.

d .Convertible notes
Effective 1 January 2005
We have adopted IAS 32 and IAS 39 effective 1 January 2005, with no restatement of
comparative information in prior periods. With the adoption of IAS 32 and IAS 39, the
6.5% Convertible Notes are analyzed into a debt component and a separate embedded
conversion option component. Under IFRS, prior to 28 October 2005, the conversion
option in the 6.5% Convertible Notes was classified as a derivative within liabilities and
fair valued through the income statement at each reporting period. The finance cost for
the 6.5% Convertible Notes also includes an amortization charge for the discount between
the initial fair value of the debt component of the 6.5% Convertible Notes and the
proceeds received on issue. This discount under IFRS is determined on the issue date
using a market interest rate for an equivalent non-convertible note, and is amortized along
with issuance costs up to the maturity of the notes using the effective interest rate method,

such that the discounted carrying value of the debt will accrete to the principal amount
over the period to the maturity date. This initial discount, which reflects the initial fair
value of the conversion option, amounted to $128.7 million for the issue as a whole, of
which $71.7 million, approximately 55%, related to the remaining principal amount of
$254.0 million outstanding at 31 December 2005. Of this $71.7 million, an amount of
$46.4 million remains unamortized at 31 December 2005.
On 28 October 2005, we removed the cash settlement feature from the Convertible
Notes and as a result, the value of the remaining conversion option is fixed as of 28
October 2005 at $91.8 million. It will not be subsequently remeasured after this date, and
has been transferred from liabilities to shareholders equity, being the equity portion of a
compound financial instrument. This $91.8 million increase in shareholders equity
represents the initial fair value of $71.1 million of the conversion option (initial fair value
discount on the debt) on the remaining $254.0 million of principal amount of the 6.5%
Convertible Notes, plus the increasing of shareholders equity, upon the removal of the
cash settlement feature, for the net cumulative mark-to-market loss of $20.7 million on
the remaining principal amount (that had previously been expensed to shareholders
equity). As described above, the $71.1 million is being amortized to interest expense over
the period to the maturity date using the effective interest rate method. The effective
interest rate of the 6.5% Convertible Notes is 15.9%. Of this $71.1 million, $46.4 million
remains unamortized at 31 December 2005
Under U.S. GAAP, there is no separate recognition of the conversion option, as it is
deemed to be clearly and closely related to the debt instrument. As a result, there is no fair
value movement on the U.S. GAAP income statement, nor an additional finance charge
for the discount arising on separation of the instrument. Timing differences may also arise
on net gains/(charges) on debt retirements, since under U.S. GAAP such gains/(charges)
are recorded only as such transactions occur, whereas the requirement under IFRS to fair
value the conversion option during each reporting period means that such gains/(charges)
may have been partially recorded in prior period(s). The difference in shareholders equity
of $46.4 million between U.S. GAAP and IFRS at 31 December 2005 represents the
remaining unamortized initial fair value discount.
This difference will decline over time to $Nil at maturity as this discount is amortized to
interest expense under IFRS using the effective interest rate method.
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Prior to 1 January 2005 the convertible debt was accounted for under Irish GAAP on an
amortized cost basis until extinguished on conversion or maturity. Therefore, there was no
difference in the accounting treatment under Irish GAAP and U.S. GAAP.
e. Acquired product rights and finance charges
Under IFRS, contingent and potential product payments which are likely to be made in
the future are recognized as a liability on a time discounted basis, with a corresponding
finance charge being expensed annually. The contingent liabilities are released if the
related assets are sold. Under U.S. GAAP, such contingent payments are not recognized
in the financial statements until the related contingencies are resolved.
f. Share-based payments
IFRS requires that the fair value of share-based payments is expensed to the income
statement over the period the related services are received, together with a corresponding
increase in equity. There is no corresponding charge for share-based payments under U.S.
GAAP for the periods presented. We will implement U.S. GAAPs Statement of Financial
Accounting Standards (SFAS) No.123R, Share-Based Payment-An Amendment of FASB
Statements No. 123 and 95, effective 1 January 2006. This standard will require us to
expense the fair value of share-based payments, rather than using the intrinsic value
method as previously allowed. Therefore, from 1 January 2006, we will record a similar
share-based compensation expense under both IFRS and U.S. GAAP.
g. Discontinued operations
Under IFRS, a discontinued operation is a component of a company that either has been
disposed of or is classified as held for sale and (i) represents a separate major line of
business or geographical area of operations, (ii) is part of a single coordinated plan to
dispose of a separate major line of business or geographical area of operations, or (iii) is a
subsidiary acquired exclusively with a view to resale. Under U.S. GAAP, a discontinued
operation is a component of an entity whose operations and cash flows have been or will
be eliminated from the ongoing operations of the entity and the entity will not have any
significant continuing involvement in the operations of the component after its disposal.
As the criteria for the determination of discontinued operations are different under IFRS
and U.S. GAAP, the products and businesses treated as discontinued operations differ
under each. There are no reconciling differences to total net income/(loss) or shareholders
equity between IFRS and U.S. GAAP related to discontinued operations. However, the
split of net income/(loss) between continuing operations and discontinued operations
differs under both GAAPs.

h. Held for sale assets
A presentation difference arises between IFRS and U.S. GAAP on assets classified as
held for sale. Under IFRS, comparatives are not restated to reflect the classification as
held for sale at a reporting date, whereas under U.S. GAAP comparatives are restated to
reflect current held for sale classifications.

